- Home
- / Evelo Biosciences
Evelo Biosciences
Stock Price
$0
2024-10-29
Market Capitalization
$3.8 K
2024-10-29
Evelo Biosciences Summary
Company Summary
- Overview
- Evelo Biosciences is a biotechnology company that develops oral biologics for the treatment of inflammatory diseases and cancer. It offers orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut.
- Type
- Public
- Status
- Active
- Founded
- 2015
- HQ
- Cambridge, MA, US | view all locations
- Website
- https://evelobio.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Mark Bodmer, President of R&D, Chief Scientific Officer
Julie Carretero, Chief People Officer
Mark Plinio, Chief Commercial Officer
Operating MetricsView all
Phase I Trials Products (Inflammation and Immunology)
1
66.7%
FY, 2021
Product (Inflammation)
4
42.9%
FY, 2021
R&D Expenses (Oncology programs)
$84K
90.8%
Q1, 2022
LocationsView all
2 locations detected
Cambridge, MA HQ
United States
620 Memorial Dr
London, England
United Kingdom
2 Royal College St
Evelo Biosciences Financials
Summary Financials
- Net income (Q3, 2023)
- ($12.4M)
- Cash (Q3, 2023)
- $17.3M
- EBIT (Q3, 2023)
- ($11.2M)
- Enterprise value
- $16.7M